Alkaline phosphatase (ALP) =< 2.5 x ULN measured within 28 days prior to randomization
Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the ULN and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (in the case of liver metastases less than or equal to 5 X ULN). In case ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3× the ULN (in the case of liver metastases ?5× the ULN). Participants with bone metastases with ALP values greater than 3 times can be included.
Alkaline phosphatase (ALP) =< 3.0 x ULN
Alkaline phosphatase (ALP) =< 5.0 x ULN, at the screening visit
Alkaline phosphatase (ALP) ? 2.5 × ULN (? 5 × ULN if disease-related/in the case of liver metastases).
Patients with isolated elevations in alkaline phosphatase (ALP) < 5 x ULN in the presence of bony disease are not excluded from participating in the study
Serum alkaline phosphatase (ALP) > 2 x ULN
Alkaline phosphatase (ALP) =< 2.5 x ULN or =< 5.0 x ULN for patients with bone metastases
Serum alkaline phosphatase (ALP) =< UNL or =< 2.5 x upper limit of normal (ULN) in case of liver and bone metastases
Alkaline phosphatase (ALP) > or = 5 x upper limit of normal (ULN).
Alkaline phosphatase (ALP) =< 5.0 x ULN
Within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase (ALP) =< 2.0 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: ALP =< 5 x ULN
Total bilirubin and alkaline phosphatase (ALP) =< 2 x ULN or =< 3 x ULN for Gilbert's disease
Alkaline phosphatase (ALP) < 2.5 x ULN
Alkaline phosphatase (ALP) =< 2.5 x ULN for the laboratory\r\n* Note: If ALP is > 1.5 x ULN, imaging to rule out bone and liver metastasis is required
Alkaline phosphatase =< 2.5 x ULN with the following exception; alkaline phosphatase (ALP) =< 5 x ULN in patients with bone metastases
Alkaline phosphatase (ALP) =< 2.5 x ULN
Alkaline phosphatase (ALP) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies).
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (Alp) =< 2.5 x upper limit of normal (ULN)
Alkaline phosphatase (ALP) =< 2 x ULN
CAPMATINIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 5 x ULN
CERITINIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 5 x ULN
PHASE I: Alkaline phosphatase (ALP) < 2.5 x ULN
Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST) or alkaline phosphatase (ALP) > 2.5 ULN without hepatic metastases or ALT, AST or ALP > 5 ULN with hepatic metastases
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (ALP) =< 3 x ULN; if ALP is > 3 x ULN, gamma glutamyltransferase (GGT) must be checked and be =< 3 x ULN (must be within 7 days of MLA)
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (ALP) < 5 x upper limit of normal
Alkaline phosphatase (ALP) < 5 x normal
Alkaline phosphatase (ALP) levels > 2.5 × ULN.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and Alkaline Phosphatase (ALP) must be within the range allowing for eligibility: ALP normal AND AST or ALT =< 5 x ULN; ALP =< 3.5 x ULN AND AST or ALT =< 1.5 x ULN; OR ALP =< 5 x ULN AND ALT or AST =< ULN
Within 14 days prior to first dose of study drug treatment: Alkaline phosphatase (ALP) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver or bone metastases: ALP =< 5 x ULN
Alkaline phosphatase (ALP) < 3 x ULN
DOSE ESCALATION COHORT: Alkaline phosphatase (ALP) ? 2.5 X ULN
Alkaline phosphatase (ALP) > 250 U/L
AST(SGOT), ALT(SGPT), or alkaline phosphatase (ALP) ? 2.5 x ULN.
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ? 3 x ULN (? 5 x ULN if participant has liver metastases). If ALP is > 3 x ULN (in the absence of liver metastases) or > 5 x ULN (in the presence of liver metastases) AND participants are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULRR or alkaline phosphatase (ALP) > 2.5 x ULRR
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment, with the following exceptions: patients with documented liver metastases: AST and ALT =< 5 x ULN; patients with documented liver or bone metastases: alkaline phosphatase (ALP) =< 5 x ULN
Alkaline phosphatase (ALP) ? 3.0 × ULN (< 5 × ULN if isolated ALP increase, i.e., without ALT/AST or bilirubin increase).
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN if participant has liver metastases). If ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of total ALP.
Alkaline phosphatase (ALP) >5 xULN
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor-related
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
Alkaline phosphatase (ALP) =< 2.5 x ULN (within 7 days prior to registration)
Alkaline phosphatase (ALP) limit < 2.5 x ULN or =< 5.0 x ULN if liver metastases are present
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?2.5 × ULN. For subjects with bone metastases and/or suspected disease-related liver or biliary involvement, ALP must be ?5 × ULN.
If bone metastases are present and liver function is otherwise considered adequate by the Investigator then elevated alkaline phosphatase (ALP) will not exclude the patient.
Alkaline phosphatase (Alp) =< 2.5 x ULN
Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
Alkaline phosphatase (Alp) =< 2.5 x ULN
Alkaline phosphatase (ALP) ?5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
Alkaline phosphatase (ALP) < 3 x UNL
Alkaline phosphatase (ALP) < 5 x upper limit of normal
Alkaline phosphatase (ALP) =< 2.5 x ULN, with the following exceptions: patients with documented liver or bone metastases: ALP =< 5 x ULN
Alkaline phosphatase (ALP) < 5 x ULN
ALP ? 3 x ULN or ? 5 x ULN if bone metastasis is present
Alkaline phosphatase =< 3 ULN; if total ALP is > 3 x ULN (in the absence of liver metastasis) or > 5 x ULN in subjects with liver metastasis AND the subject is known to have bone metastases, then liver ALP iso-enzyme should be used to assess liver function rather than total ALP
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN. For total ALP greater than 3 times ULN, the ALP liver isoenzyme must be less than or equal to 3 times ULN.
Patients enrolled without hepatic dysfunction must have laboratory test results for total bilirubin of less than the ULN, alkaline phosphatase (ALP) <=1.5x the ULN, and AST and ALT of <=the ULN.
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP): all three < 2.5 x ULRR, or < 5 x ULRR if judged by the investigator to be related to liver metastases
Bilirubin and Alkaline phosphatase (ALP) =< 2 x ULN
Alkaline phosphatase (ALP) =< 5.0 x ULN
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3 × ULN (?5 × ULN if participant has liver metastases). If ALP is >3 × ULN (in the absence of liver metastases) or >5 × ULN (in the presence of liver metastases) AND participants are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
Alkaline phosphatase (ALP) > 2 x ULRR, or > 4 x ULRR if judged by the investigator to be related to liver metastases
Alkaline phosphatase (ALP) > 2.5 x ULRR
Individuals with alkaline phosphatase (ALP) > 2.5 x normal upper limit any time during the previous 2 months
